[ADVERT]
Share Name Share Symbol Market Type Share ISIN Share Description
Avacta Group Plc LSE:AVCT London Ordinary Share GB00BYYW9G87 ORD 10P
  Price Change % Change Share Price Shares Traded Last Trade
  5.00 4.13% 126.00 1,454,957 16:21:00
Bid Price Offer Price High Price Low Price Open Price
124.00 128.00 127.50 119.50 121.50
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 3.64 -21.34 -8.37 319
Last Trade Time Trade Type Trade Size Trade Price Currency
17:07:25 O 43,853 126.00 GBX

Avacta (AVCT) Latest News

More Avacta News
Avacta Investors    Avacta Takeover Rumours

Avacta (AVCT) Discussions and Chat

Avacta Forums and Chat

Date Time Title Posts
21/10/202101:24Avacta – Innovative and Disruptive Technologies for Global Health Markets37,029
14/10/202122:44CV And The Deep State193
11/10/202118:28Covid-19. Ten Minute Test. Gamechanger!!66
11/10/202115:51avct The Fall!!!113
08/10/202122:51Covid-19. Ten Minute Test. Gamechanger!!19,481

Add a New Thread

Avacta (AVCT) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type
2021-10-20 16:07:25126.0043,85355,254.78O
2021-10-20 16:02:04124.003,6464,521.04O
2021-10-20 16:02:04124.003,6464,521.04O
2021-10-20 15:38:05125.3050,00062,650.00O
2021-10-20 15:35:29126.0024,11730,387.42UT
View all Avacta trades in real-time

Avacta (AVCT) Top Chat Posts

DateSubject
20/10/2021
09:20
Avacta Daily Update: Avacta Group Plc is listed in the Pharmaceuticals & Biotechnology sector of the London Stock Exchange with ticker AVCT. The last closing price for Avacta was 121p.
Avacta Group Plc has a 4 week average price of 104p and a 12 week average price of 97p.
The 1 year high share price is 290p while the 1 year low share price is currently 90p.
There are currently 253,236,345 shares in issue and the average daily traded volume is 1,431,369 shares. The market capitalisation of Avacta Group Plc is £319,077,794.70.
18/10/2021
13:25
pwhite73: deme1 - I'm not sure you fully appreciate what the delay is and why AVCT hasn't been approved already. All the approved test providers are using reagents/antibodies (this is a stipulation by the government) to determine to what extent someone is infected with the virus. Their PCR machines are also using reagents/antibodies. What adaptions will be needed to use affimers that are unique only to AVCT. AS has already advised the market is crowded with LFTs so will HUA generate any additional sales for AVCT. If you check out the list of existing approved test providers they advise which LFTs they are using. For AVCT to break into this market existing contracts will need to be terminated and AS has already stated the AVCT LFT is one of the more expensive due to its higher quality. Any announcement of HUA approval may cause a small rise in the share price but its not going to last long. You need to think seriously about your investment here.
12/10/2021
13:01
pwhite73: volsung - The share price finds a platform where it stabilises but its a trick to entice PIs to purchase. Once enough PIs are in at these recent lows down she goes again to hit another platform. AVCT has a market cap of £280 million. Novacyt which is actually selling Covid devices in the tens of £millions has a market cap of £180 million. Another £100 million is to be wiped off the AVCT market cap over the coming months.
10/10/2021
13:15
pwhite73: lith - Any BB can weather the deramping storm if the share price is rising, it gives the longs something to counter with and proves them right. When the share price has collapsed more than 50% its a losing battle.
07/10/2021
09:40
pwhite73: grosstonnage - "I’m seeing these low prices as an opportunity to add to my holding" These prices are not low. Read the two statements made buy David Budd of GDR and look at the difference between the two share prices. David Budd CEO Genedrive 22/05/2020 Share price 235p - "The development teams at genedrive and at Cytiva have worked tirelessly over the past 2 months to develop our unique product that has the potential to streamline lab testing, improve quality, and ultimately allow more people to be tested. CE marking was achieved with performance studies and validations that will also support regulatory applications in other jurisdictions, such as Emergency Use Authorisation with the USA FDA and Emergency" David Budd CEO Genedrive 29/09/2021 Share price 25p - "Our thanks go to the shareholders that have participated in this Open Offer, which has resulted in a further GBP1.1 million of gross proceeds being raised. The net proceeds of the Fundraising will allow us to further fund our Genedrive(R) COV19-ID Kit, support the commercial roll out of the AIHL test including new business development and additional product development, commercialisation efforts and general corporate costs.""
03/10/2021
12:38
pwhite73: What's driving the price down is the widely held belief among institutions and private investors that AVCT cannot deliver on its Covid LFT project. It was this project that caused the share price to soar from 20p in April 2020 to 280p in May 2021. If the company still cannot gain any traction 13 months later then why is the share price still six times higher than 20p. With regards to manufacturing at GAD you cannot hide one million LFTs coming off the production line every month from August 2021. People gossip, workers at GAD would be using the LFTs themselves and it would be in the regional papers and online. I challenge you all to find a single story anywhere of Covid LFTs currently being manufactured at Thurleigh Bedfordshire. Speak Later
30/9/2021
13:14
tickboo: - AVCT LFT has market leading performance - significant commercial opportunity remains- UK manufax capacity 2 - 3m per month, can be scaled in UK and abroad- Commercial traction is building- "Extremely pleased" to have achieved goal of bringing AVCT to clinical stage for its cancer therapies- IND filing for AVA6000 before the end of 2021 for P1 study in the US, "confident we will achieve that"- Strong balance sheet - support core business and working capital for Covid testing opportunityQuestionsHow are you following PKP and toxicology of AVA6000? Measuring levels of dox in plasma and urine - straightforward way to do that in 72 hours post-dose and measure how they are eliminated by the bodyWhen will shareholders be given indication of how AVA6000 is going?Positive guidance today, totally inappropriate to talk about data today as there is only a single patient currently having been dosed, but we are very pleased with progress - new sites and new patients in trial soon, no concern re: scheduling, we will update the market as soon as we possibly can, escalating dose and starting next cohort is strong indicator that regulators are happy with safetyWhen is HUA expected for LFT, and any clarity on why the process has taken so long?Additional lay user study focuses on usability rather than clinical validation, this is combined with technical data for test performance, full technical file submitted for review - M19 have led this process and done an outstanding job - taken a long time but notifiable body review can take many months even under 'normal times' - 'sincerely hope' we are close but it's out of our handsWhy has there seemingly been no commercial interest in LFT?This is just not true to say there has been no commercial interest, we are clearly not the first test to market but we are an extremely good test, will take time to build market share, business development, marketing, approvals in new territories and potentially licensing. Covid testing will be around for years, seasonal element and risk of new variants. This is a long term commercial opportunity and we will build on itComment on significant share price decline and how you will address it?Falling share price clearly not desirable, however AS remains focused on driving business forward, which means a profitable diagnostics division and unlocking value in therapeutics initially via success of AVA6000 - this will unlock a further 'incredible' pipeline. Potential value of Precision platform working well in humans and enhancing the effects of chemo 'dwarves' the value of Covid testing
30/9/2021
13:09
pwhite73: dalep176 - The direction of the share price correctly reflects what's going on. The share price and market cap rocketed as the company leveraged its products to cash in on the Covid bonanza. For political and technological reasons it has not been able to commercialise its Covid projects. The share price is receding from whence it came. It should be reflecting only the AVA6000 phase 1 trials and what little revenue is obtained from the Affimers. I said a while back that clinical trials in the UK carry no commercial or scientific weight with the US. I note the company has now decided to make an application to initiate AVA6000 Phase I trials in the US. It will need to do this if US money and US companies are to climb on board. It is a step in the right direction but commercially the Phase I trials have technically been put back one year.
29/9/2021
15:44
blackvulture: The dilution doesn't matter if the CEO is looking after the share price. That's what's important to small shareholders. Not the market cap or the number of shares in issue but the share price. Brad was looking after the share price that's the sole reason why I bought in without any business to speak of. That's the difference between the new team and the old. The old team drove the share price down from 0.40p to 0.006p whilst paying themselves £200k p.a each. They cared not one iota and to this very day still don't as their recent actions to destroy what's left of ICON proves.
28/9/2021
11:37
amanitaangelicus: Whitey ...any fool knows we need some bread, preferably organic, wholemeal, granary,poppy seeded with added ginseng rather than Nisa white, el cheapo. The mkt hates unfulfilled promises. Why do you think the share price is where it.s at? We.re not being valued at 350m anymore! If you were being brutal, you could look at the share price pre covid, add in the 48 million raise, the progress in C stuff and other new affimer applications. We.ve got forgotten Sth Korean stuff ongoing too. Does this support the current 300m mkt cap? Looking for 30m net profit for me. What achieves this? Juicy LFT sales ...for me, 2m/ month LFT sales isnt too onerous. Our cash, whatever it turns out to be, would be protected as the C phases progresses. I admit, there s lots of if.s and but.s. Sadly, your focus is wholly on the ' buts' and are only here to put doubt into pi.s minds to support your short spreadbet. Personally, I think you have zero interest here, but are addicted to the share now, like many here, despite their protestations otherwise. Try for balance ...it.ll help your finances in the long run, and for goodness sake have at least 4 different shares in your portfolio... preferably 8 if it.s fun money. Go away.
28/9/2021
09:19
amanitaangelicus: This will relegate pcr.s to voi/voc watch, which is still a vitally important necessity. Ignore these at your peril. PCR sales will plummet as cheap LFT.s release monies for nhs appointments, other treatments, cash for operations. This will be massive. Big Al just needs to have a fling or 2 with key members of the elite Tory, Oxbridge network to secure a sale or 2. Potential revenues looking better relative to mkt cap, cash position and costs going forward. The LFT model should work well for generating cash. My only concern, and sorry but it still remains, are just how price sensitive is the demand for LFTs. Elasticity is key here. 2million/ month would do nicely, but until more production announcements/ agreements are made, this is unlikely to be achieved. There.s no reason why we cant sell 60m LFTs a year, utilising the international mkts. Covid is NOT going away. The unvacced world is churning out new voi s on a daily basis remember. We can change our LFT affimers for any eventuality I suspect. Looking canny - just need to survive Thursday s results which will be well known now by most Avacta invested ii.s and those connected parties. share price should be tending towards known expectations now. If this isnt the case, and the share price tumbles on Thursday am, wait for it to settle and pile in. It.s not if now, but when we.ll become a major LFT player. IP will rise not to mention cash flow and profitability. Risk is marginal now. Therapies are, perversely, our biggest threat! GLA.
Avacta share price data is direct from the London Stock Exchange
ADVFN Advertorial
Your Recent History
LSE
AVCT
Avacta
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20211021 03:06:33